Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 10944-10957

  Kruck, Stephan ^a   Eyrich, Christian ^a   Scharpf, Marcus ^a   Sievert, Karl Dietrich ^a   Fend, Falco ^a   Stenzl, Arnulf ^a   Bedke, Jens ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Carcinogenesis; Prognosis; Renal cell cancer; Targeted therapy; Wnt1; catenin

Indexed keywords

BETA CATENIN; WNT1 PROTEIN; WNT1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SCORING SYSTEM; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR NECROSIS; TUMOR VOLUME; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; KIDNEY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BETA CATENIN; CARCINOMA, RENAL CELL; CELL MEMBRANE; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; WNT1 PROTEIN;

EID: 84878427672     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140610944     Document Type: Article

References (41)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA A Cancer J. Clin. 2012, 62, 10-29.
2. Kruck, S.; Bedke, J.; Kuczyk, M.A.; Merseburger, A.S. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer Ther. 2012, 12, 777-785.
3. Bilim, V.; Kawasaki, T.; Katagiri, A.; Wakatsuki, S.; Takahashi, K.; Tomita, Y. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin. Cancer Res. 2000, 6, 460-466.
4. Kim, Y.S.; Kang, Y.K.; Kim, J.B.; Han, S.A.; Kim, K.I.; Paik, S.R. Beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol. Int. 2000, 50, 725-730.
5. Aaltomaa, S.; Lipponen, P.; Kärjä, V.; Lundstedt, S.; Lappi, J.; Kosma, V.-M. The expression and prognostic value of α-, β-and γ-catenins in renal cell carcinoma. Anticancer Res. 2004, 24, 2407-2414.
6. Bruder, E.; Moch, H.; Ehrlich, D.; Leuschner, I.; Harms, D.; Argani, P.; Briner, J.; Graf, N.; Selle, B.; Rufle, A.; et al. Wnt signaling pathway analysis in renal cell carcinoma in young patients. Modern Pathol. An Off. J. USA Can. Acad. Pathol. Inc. 2007, 20, 1217-1229.
7. Lian, X.; Duan, X.; Wu, X.; Li, C.; Chen, S.; Wang, S.; Cai, Y.; Weng, Z. Expression and clinical significance of von Hippel-Lindau downstream genes: Jade-1 and beta-catenin related to renal cell carcinoma. Urology 2012, 80, e487-e413.
8. Hsu, R.J.; Ho, J.Y.; Cha, T.L.; Yu, D.S.; Wu, C.L.; Huang, W.P.; Chu, P.; Chen, Y.H.; Chen, J.T.; Yu, C.P. WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/beta-catenin pathway. PLoS One 2012, 7, e47649.
9. Zang, T.; Zhuang, L.; Zhang, Z.; Xin, D.; Guo, Y. Expression of beta-catenin in renal cell carcinoma. Chin. Med. J. 2001, 114, 152-154.
10. Thevenod, F.; Chakraborty, P.K. The role of Wnt/beta-catenin signaling in renal carcinogenesis: lessons from cadmium toxicity studies. Curr. Mol. Med. 2010, 10, 387-404.
11. Valenta, T.; Hausmann, G.; Basler, K. The many faces and functions of beta-catenin. EMBO J. 2012, 31, 2714-2736.
12. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469-480.
13. Satoh, S.; Daigo, Y.; Furukawa, Y.; Kato, T.; Miwa, N.; Nishiwaki, T.; Kawasoe, T.; Ishiguro, H.; Fujita, M.; Tokino, T.; et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 2000, 24, 245-250.
14. Cox, S.N.; Sallustio, F.; Serino, G.; Pontrelli, P.; Verrienti, R.; Pesce, F.; Torres, D.D.; Ancona, N.; Stifanelli, P.; Zaza, G.; et al. Altered modulation of WNT-[beta]-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int. 2010, 78, 396-407.
15. Choi, H.; Chun, Y.S.; Kim, T.Y.; Park, J.W. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res. 2010, 70, 10101-10111.
16. Herzlinger, D.; Qiao, J.; Cohen, D.; Ramakrishna, N.; Brown, A.M. Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. Dev. Biol. 1994, 166, 815-818.
17. Katoh, M. Expression and regulation of WNT1 in human cancer: Up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int. J. Oncol. 2003, 22, 209-212.
18. Chen, S.; Guttridge, D.C.; You, Z.; Zhang, Z.; Fribley, A.; Mayo, M.W.; Kitajewski, J.; Wang, C.Y. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J. Cell Biol. 2001, 152, 87-96.
19. Chen, G.; Shukeir, N.; Potti, A.; Sircar, K.; Aprikian, A.; Goltzman, D.; Rabbani, S.A. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma. Cancer 2004, 101, 1345-1356.
20. Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31, 99-109.
21. Röhrs, S.; Kutzner, N.; Vlad, A.; Grunwald, T.; Ziegler, S.; Müller, O. Chronological expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3. Cell Biol. Int. 2009, 33, 501-508.
22. Janssens, N.; Andries, L.; Janicot, M.; Perera, T.; Bakker, A. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2004, 25, 161-171.
23. Janssens, N.; Janicot, M.; Perera, T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Investig. New Drugs 2006, 24, 263-280.
24. Inoki, K.; Ouyang, H.; Zhu, T.; Lindvall, C.; Wang, Y.; Zhang, X.; Yang, Q.; Bennett, C.; Harada, Y.; Stankunas, K.; et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126, 955-968.
25. Mizushima, T.; Nakagawa, H.; Kamberov, Y.G.; Wilder, E.L.; Klein, P.S.; Rustgi, A.K. Wnt-1 but not epidermal growth factor induces beta-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002, 62, 277-282.
26. Heuberger, J.; Birchmeier, W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb. Perspect. Biol. 2010, 2, a002915.
27. Kraus, C.; Liehr, T.; Hulsken, J.; Behrens, J.; Birchmeier, W.; Grzeschik, K.H.; Ballhausen, W.G. Localization of the human beta-catenin gene (CTNNB1) to 3p21: A region implicated in tumor development. Genomics 1994, 23, 272-274.
28. Maestro, M.L.; del Barco, V.; Sanz-Casla, M.T.; Moreno, J.; Adrover, E.; Izquierdo, L.; Zanna, I.; Fernandez, C.; Redondo, E.; Blanco, J.; et al. Loss of heterozygosity on the short arm of chromosome 3 in renal cancer. Oncology 2000, 59, 126-130.
29. Zeitlin, B.D.; Ellis, L.M.; Nör, J.E. Inhibition of vascular endothelial growth factor receptor-1/Wnt/β-catenin crosstalk leads to tumor cell death. Clin. Cancer Res. 2009, 15, 7453-7455.
30. Kawano, Y.; Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 2003, 116, 2627-2634.
31. Dahl, E.; Wiesmann, F.; Woenckhaus, M.; Stoehr, R.; Wild, P.J.; Veeck, J.; Knuchel, R.; Klopocki, E.; Sauter, G.; Simon, R.; et al. Frequent loss of SFRP1 expression in multiple human solid tumours: Association with aberrant promoter methylation in renal cell carcinoma. Oncogene 2007, 26, 5680-5691.
32. Awakura, Y.; Nakamura, E.; Ito, N.; Kamoto, T.; Ogawa, O. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol. Rep. 2008, 20, 1257-1263.
33. Gumz, M.L.; Zou, H.; Kreinest, P.A.; Childs, A.C.; Belmonte, L.S.; LeGrand, S.N.; Wu, K.J.; Luxon, B.A.; Sinha, M.; Parker, A.S.; et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 4740-4749.
34. Yamamura, S.; Kawakami, K.; Hirata, H.; Ueno, K.; Saini, S.; Majid, S.; Dahiya, R. Oncogenic functions of secreted Frizzled-related protein 2 in human renal cancer. Mol. Cancer Ther. 2010, 9, 1680-1687.
35. Kawakami, K.; Hirata, H.; Yamamura, S.; Kikuno, N.; Saini, S.; Majid, S.; Tanaka, Y.; Kawamoto, K.; Enokida, H.; Nakagawa, M.; et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res. 2009, 69, 8603-8610.
36. Hirata, H.; Hinoda, Y.; Nakajima, K.; Kawamoto, K.; Kikuno, N.; Ueno, K.; Yamamura, S.; Zaman, M.S.; Khatri, G.; Chen, Y.; et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int. J. Cancer. 2011, 128, 1793-1803.
37. Hirata, H.; Hinoda, Y.; Nakajima, K.; Kawamoto, K.; Kikuno, N.; Kawakami, K.; Yamamura, S.; Ueno, K.; Majid, S.; Saini, S.; et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009, 15, 5678-5687.
38. Ueno, K.; Hirata, H.; Majid, S.; Chen, Y.; Zaman, M.S.; Tabatabai, Z.L.; Hinoda, Y.; Dahiya, R. Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol. Carcinogen. 2011, 50, 449-457.
39. Ronkainen, H.; Kauppila, S.; Hirvikoski, P.; Vaarala, M.H. Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma. J. Exp. Clin. Cancer Res. CR 2010, 29, 2.
40. Kruck, S.; Merseburger, A.S.; Hennenlotter, J.; Scharpf, M.; Eyrich, C.; Amend, B.; Sievert, K.D.; Stenzl, A.; Bedke, J. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int. 2012, 109, 1565-1570.
41. Cheng, S.L.; Shao, J.S.; Cai, J.; Sierra, O.L.; Towler, D.A. Msx2 exerts bone anabolism via canonical Wnt signaling. J. Biol. Chem. 2008, 283, 20505-20522.